News | April 08, 2022
Cadila Pharma launches world’s first three-dose rabies vaccine
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
The recombinant nanoparticle-based rabies G protein vaccine is prepared using virus-like particle technology.
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
No new studies have been requested
It paves the way for an industry Code of Good Practice
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
These courses are for pre-selected candidates who have completed their MBBS with an additional 2 years of surgical experience training
U.S. NIAID-sponsored trial will evaluate heterologous booster regimens, including NVX-CoV2373, after primary series with current USFDA approved or emergency use authorized-vaccines
Subscribe To Our Newsletter & Stay Updated
